Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, August 05, 2020
Horizon Discovery announced TrueBinding has signed a set of commercial licenses for Horizon’s cGMP-compliant CHOSOURCE platform.
read more
Monday, December 14, 2020
Horizon Discovery Group has granted two commercial licenses for its cGMP-compliant CHOSOURCE platform to Sanyou Biopharmaceuticals.
read more
Wednesday, April 15, 2020
Horizon Discovery announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™ platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-...
read more
Horizon Discovery has signed a collaboration and license agreement with Mammoth Biosciences to access Mammoth’s novel CRISPR platform.
read more
Monday, September 30, 2019
Horizon Discovery Group announced the full commercial licensing to Glenmark of its gene-edited Glutamine Synthetase knockout Chinese Hamster Ovary K1 cell line.
read more
Wednesday, April 01, 2020
Horizon Discovery and Pharmahungary Group announced positive early-stage results for a novel micro-RNA therapeutic for ischemic heart diseases.
read more
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced it has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and...
read more
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced an important milestone, commemorating five years of providing biosimilars to the European market and delivery of more than five ...
read more
Hoth reached an agreement with Voltron to form a joint venture entity to commence preclinical studies for the development of vaccine prospects to prevent the COVID-19.
read more
Hoth has executed an agreement with Reprocell to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn's disease patients.
read more
Wednesday, March 25, 2020
Hoth has reached an agreement with Voltron to form a joint venture entity to commence preclinical studies for the development of vaccine prospects to prevent, intercept or treat the COVID-19.
read more
Hoth Therapeutics, a patient-focused biopharmaceutical company, announced that it has received approval from the FDA for a protocol change in its Phase 2a clinical trial of HT-001.
read more
Hoth Therapeutics has signed contracts with providers for production of their BioLexa therapeutic, in preparation for upcoming toxicology and clinical studies.
read more
The House on Tuesday approved a bipartisan bill that would update regulation of harmful chemicals for the first time in nearly 40 years.
read more
Hovione and Firstgene Life Sciences announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC), a therapeutic indication developed by ...
read more